Acquired by AstraZeneca in July 2021
ALXN - Alexion Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
ALXN price evolution
ALXN
| (in millions $) | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 | 30 Jun 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3429.6 | $2964.5 | $2268 | $2825 |
| Short term investments | $39.7 | $34.9 | $28.9 | $26.8 |
| Net receivables | $1473 | $1409.3 | $1437.1 | $1372.2 |
| Inventory | $803.9 | $775.7 | $729 | $577.7 |
| Total current assets | $6452.6 | $5833 | $5067.8 | $5367.9 |
| Long term investments | $132.2 | $184.2 | $141.4 | |
| Property, plant & equipment | $1461.6 | $1461.9 | $1434.6 | $1406.3 |
| Goodwill & intangible assets | $8148.4 | $8102.5 | $8157.3 | $7134.9 |
| Total noncurrent assets | $12197.6 | $12270 | $12480.6 | $11335.3 |
| Total investments | $39.7 | $34.9 | $28.9 | $26.8 |
| Total assets | $18650.2 | $18103 | $17548.4 | $16703.2 |
| Current liabilities | ||||
| Accounts payable | $125.3 | $118.6 | $89.2 | $861.6 |
| Deferred revenue | ||||
| Short long term debt | $143.2 | $142.4 | $138.6 | $126.8 |
| Total current liabilities | $1426.2 | $1624.7 | $1331 | $1120.1 |
| Long term debt | $2559.6 | $2596.7 | $2629.1 | $2481 |
| Total noncurrent liabilities | $4793 | $4827.1 | $5142.5 | $5092.3 |
| Total debt | $2702.8 | $2739.1 | $2767.7 | $2607.8 |
| Total liabilities | $6219.2 | $6451.8 | $6473.5 | $6212.4 |
| Shareholders' equity | ||||
| Retained earnings | $5879.2 | $5243.2 | $4707.4 | $4129.3 |
| Other shareholder equity | -$85.2 | -$124.6 | -$119.2 | -$110.9 |
| Total shareholder equity | $12416.8 | $11651.2 | $11074.9 | $10490.8 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2964.5 | $2685.5 | $1365.5 | $584.4 |
| Short term investments | $34.9 | $64 | $198.3 | $889.7 |
| Net receivables | $1409.3 | $1243.2 | $922.3 | $726.5 |
| Inventory | $775.7 | $627.6 | $472.5 | $460.4 |
| Total current assets | $5833 | $5076.4 | $3385 | $2953.9 |
| Long term investments | $184.2 | $120.1 | $12.5 | |
| Property, plant & equipment | $1461.9 | $1367.3 | $1471.5 | $1325.4 |
| Goodwill & intangible assets | $8102.5 | $8381.7 | $8678.7 | $8991.8 |
| Total noncurrent assets | $12270 | $12468.2 | $10546.9 | $10629.4 |
| Total investments | $34.9 | $64 | $198.3 | $889.7 |
| Total assets | $18103 | $17544.6 | $13931.9 | $13583.3 |
| Current liabilities | ||||
| Accounts payable | $118.6 | $966.7 | $698.2 | $70.8 |
| Deferred revenue | $15.9 | |||
| Short long term debt | $142.4 | $126.7 | $343.8 | $167.4 |
| Total current liabilities | $1624.7 | $1194.3 | $1174 | $952.5 |
| Long term debt | $2596.7 | $2539.1 | $2862.7 | $3063.6 |
| Total noncurrent liabilities | $4827.1 | $5078.5 | $3592.6 | $3737.7 |
| Total debt | $2739.1 | $2665.8 | $3206.5 | $3231 |
| Total liabilities | $6451.8 | $6272.8 | $4766.6 | $4690.2 |
| Shareholders' equity | ||||
| Retained earnings | $5243.2 | $4639.8 | $2325.8 | $2242.1 |
| Other shareholder equity | -$124.6 | -$66.8 | -$9.7 | -$34.4 |
| Total shareholder equity | $11651.2 | $11271.8 | $9165.3 | $8893.1 |
| (in millions $) | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 | 30 Jun 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1636.5 | $1591.8 | $1588.7 | $1444.6 |
| Cost of revenue | $125.4 | $152.2 | $144.7 | $144.9 |
| Gross Profit | $1511.1 | $1439.6 | $1444 | $1299.7 |
| Operating activities | ||||
| Research & development | $289.1 | $295 | $285.9 | $221.1 |
| Selling, general & administrative | $342.9 | $444.4 | $334.2 | $301.4 |
| Total operating expenses | $865.7 | $801.3 | $750.5 | $2654.1 |
| Operating income | $645.4 | $638.3 | $693.5 | -$1354.4 |
| Income from continuing operations | ||||
| EBIT | $776.5 | $618.3 | $694.5 | -$1328.5 |
| Income tax expense | $113.4 | $54.8 | $88.8 | -$284 |
| Interest expense | $27.1 | $27.7 | $27.6 | $23.6 |
| Net income | ||||
| Net income | $636 | $535.8 | $578.1 | -$1068.1 |
| Income (for common shares) | $636 | $535.8 | $578.1 | -$1068.1 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6069.9 | $4991.1 | $4131.2 | $3551.1 |
| Cost of revenue | $553.5 | $394.5 | $374.3 | $454.2 |
| Gross Profit | $5516.4 | $4596.6 | $3756.9 | $3096.9 |
| Operating activities | ||||
| Research & development | $1002.9 | $886 | $730.4 | $878.4 |
| Selling, general & administrative | $1399.9 | $1261.1 | $1111.8 | $1094.4 |
| Total operating expenses | $4837.7 | $2464.6 | $3370.8 | $2428.5 |
| Operating income | $678.7 | $2132 | $386.1 | $668.4 |
| Income from continuing operations | ||||
| EBIT | $673.7 | $2256.6 | $340.4 | $646.2 |
| Income tax expense | -$34.4 | -$225.5 | $164.6 | $104.5 |
| Interest expense | $104.7 | $77.8 | $98.2 | $98.4 |
| Net income | ||||
| Net income | $603.4 | $2404.3 | $77.6 | $443.3 |
| Income (for common shares) | $603.4 | $2404.3 | $77.6 | $443.3 |
| (in millions $) | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 | 30 Jun 2020 |
|---|---|---|---|---|
| Net income | $636 | $535.8 | $578.1 | -$1068.1 |
| Operating activities | ||||
| Depreciation | $75.6 | $75.1 | $75.2 | $89.8 |
| Business acquisitions & disposals | -$1274.2 | |||
| Stock-based compensation | $76.6 | $85.5 | $70.6 | $67.4 |
| Total cash flows from operations | $637.6 | $840.5 | $822.8 | $790 |
| Investing activities | ||||
| Capital expenditures | -$20.2 | -$77.5 | -$10.8 | -$6.2 |
| Investments | -$3.7 | -$3.1 | $17.6 | $20.7 |
| Total cash flows from investing | -$133.9 | -$80.6 | -$1267.4 | $14.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.2 | -$39.9 | -$64.3 | -$243.6 |
| Net borrowings | -$32.6 | -$32.7 | -$32.6 | -$32.7 |
| Total cash flows from financing | -$18.7 | -$73.8 | -$107.4 | -$292.5 |
| Effect of exchange rate | -$13.1 | $20 | $7.6 | $5.1 |
| Change in cash and equivalents | $471.9 | $706.1 | -$544.4 | $517.1 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | $603.4 | $2404.3 | $77.6 | $443.3 |
| Operating activities | ||||
| Depreciation | $329.4 | $376.8 | $405.3 | $496.7 |
| Business acquisitions & disposals | -$2111.9 | |||
| Stock-based compensation | $281.1 | $237 | $203 | $243.1 |
| Total cash flows from operations | $3002.9 | $2084.9 | $426 | $1115.6 |
| Investing activities | ||||
| Capital expenditures | -$106.7 | -$154.7 | -$213 | -$357.3 |
| Investments | $119.1 | $180.5 | $680.7 | -$561.1 |
| Total cash flows from investing | -$2099.5 | $9.7 | $470.5 | -$918.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$452.1 | -$386.1 | -$37.7 | -$377.7 |
| Net borrowings | -$130.6 | -$348 | -$43.8 | -$175 |
| Total cash flows from financing | -$611.9 | -$739.1 | -$102.4 | -$596.6 |
| Effect of exchange rate | $19.5 | $0.8 | -$11.2 | $17.7 |
| Change in cash and equivalents | $311 | $1356.3 | $782.9 | -$381.6 |
News
|
Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag
MSN News
24 Jul 2021
|
|
Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?
Zacks via Yahoo Finance
22 Jul 2021
|
|
ALXN vs. TECH: Which Stock Is the Better Value Option?
Zacks via Yahoo Finance
21 Jul 2021
|
|
Moderna Enters the S&P Amid Delta Variant Fears – Should You Invest?
GoBankingRates via AOL
21 Jul 2021
|
|
Moderna stock 'has taken on a life of its own,' jumps 4% in S&P debut
Yahoo Finance
21 Jul 2021
|
|
Moderna being added to S&P 500
Fox Business
21 Jul 2021
|
|
Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day
Market Watch
20 Jul 2021
|
|
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study
MSN News
18 Jul 2021
|
|
Moderna to join S&P 500, shares jump after hours
Reuters
15 Jul 2021
|
|
Moderna Climbs as S&P 500 Set to Welcome Covid Vaccine Maker
Bloomberg
15 Jul 2021
|
Fundamentals
| Market cap | $33.60B |
|---|---|
| Enterprise value | $32.87B |
| Shares outstanding | 221.02M |
| Revenue | $6.26B |
|---|---|
| EBITDA | $1.08B |
| EBIT | $760.80M |
| Net Income | $681.80M |
| Revenue Q/Q | 13.27% |
| Revenue Y/Y | 18.24% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | 5.25 |
| EV/EBITDA | 30.53 |
| EV/EBIT | 43.20 |
| P/S ratio | 5.37 |
| P/B ratio | 0.00 |
| Book/Share | 56.57 |
| Cash/Share | 15.52 |
| EPS | $3.08 |
|---|---|
| ROA | 3.84% |
| ROE | 5.98% |
| Debt/Equity | 0.55 |
|---|---|
| Net debt/EBITDA | 2.59 |
| Current ratio | 4.52 |
| Quick ratio | 3.96 |